Literature DB >> 16158948

Paracrine calcitonin in prostate cancer is linked to CD44 variant expression and invasion.

Kenneth A Iczkowski1, A Levi Omara-Opyene, Trupti R Kulkarni, Megha Pansara, Girish V Shah.   

Abstract

BACKGROUND: Calcitonin (CT) exerts an autocrine/paracrine influence on prostatic tumor invasion through coupling to transduction protein Gsalpha. Cell adhesion glycoprotein CD44 variant v7-v10 also faciliates invasion, but its modulation by the CT-Gsalpha system was unexplored.
MATERIALS AND METHODS: LnCaP, PC-3 and metastasis-derived PC-3M cell lines were studied, including cells modified therefrom: Gsalpha-QL, expressing mutant constitutively active Gsalpha protein, and CT+, overexpressing CT. CD44 variant expression was evaluated in vivo after orthotopic implantion into nude mice, and in vitro by real-time RT-PCR and Western blotting.
RESULTS: Both mRNA and protein levels of the CD44 variant were minimal in PC-3M tumor implants, but elevated in Gsalpha-QL. Exogenous CT stimulated invasion into Matrigel strongly in LnCaP and CT+, and less in PC-3 and Gsalpha-QL. By Western blot analysis, untreated Gsalpha-QL and CT+ cells overexpressed CD44 variant compared with LnCaP or PC-3. By quantitative RT-PCR, exogenous CT dose-dependently increased CD44 variant mRNA to seven-fold. Pharmacologic agents that stimulated or inhibited Gsalpha activity or stimulated adenylyl cyclase produced proportionate dose-dependent effects on both CD44 variant expression and Matrigel invasion.
CONCLUSION: This paracrine factor, acting though cyclic AMP, regulates the expression of CD44v7-10, which modulates the tumor phenotype.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16158948

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  9 in total

1.  Phenyl-methylene hydantoins alter CD44-specific ligand binding of benign and malignant prostate cells and suppress CD44 isoform expression.

Authors:  Kui Yang; Yaqiong Tang; Kenneth A Iczkowski
Journal:  Am J Transl Res       Date:  2010-01-01       Impact factor: 4.060

2.  Cell adhesion molecule CD44: its functional roles in prostate cancer.

Authors:  Kenneth A Iczkowski
Journal:  Am J Transl Res       Date:  2010-09-12       Impact factor: 4.060

3.  Dutasteride prevents the growth response to testosterone in benign and androgen-sensitive malignant prostate cells.

Authors:  Joseph M Alisky; Yaqiong Tang; Gabriel K Habermehl; Kenneth A Iczkowski
Journal:  Int J Clin Exp Med       Date:  2010-07-25

4.  Silibinin suppresses CD44 expression in prostate cancer cells.

Authors:  Alina M Handorean; Kui Yang; Eric W Robbins; Thomas W Flaig; Kenneth A Iczkowski
Journal:  Am J Transl Res       Date:  2009-01-01       Impact factor: 4.060

5.  Elevated expressions of MMP7, TROP2, and survivin are associated with survival, disease recurrence, and liver metastasis of colon cancer.

Authors:  Y J Fang; Z H Lu; G Q Wang; Z Z Pan; Z W Zhou; J P Yun; M F Zhang; D S Wan
Journal:  Int J Colorectal Dis       Date:  2009-05-07       Impact factor: 2.571

6.  MicroRNAs 373 and 520c are downregulated in prostate cancer, suppress CD44 translation and enhance invasion of prostate cancer cells in vitro.

Authors:  Kui Yang; Alina M Handorean; Kenneth A Iczkowski
Journal:  Int J Clin Exp Pathol       Date:  2008-11-26

Review 7.  Does salmon calcitonin cause cancer? A review and meta-analysis.

Authors:  G Wells; J Chernoff; J P Gilligan; D S Krause
Journal:  Osteoporos Int       Date:  2015-10-05       Impact factor: 4.507

8.  Stable alterations of CD44 isoform expression in prostate cancer cells decrease invasion and growth and alter ligand binding and chemosensitivity.

Authors:  Kui Yang; Yaqiong Tang; Gabriel K Habermehl; Kenneth A Iczkowski
Journal:  BMC Cancer       Date:  2010-01-14       Impact factor: 4.430

9.  MAP kinase pathways and calcitonin influence CD44 alternate isoform expression in prostate cancer cells.

Authors:  Eric W Robbins; Emily A Travanty; Kui Yang; Kenneth A Iczkowski
Journal:  BMC Cancer       Date:  2008-09-15       Impact factor: 4.430

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.